Allogeneic BMT is an effective immunotherapy for childhood leukemia. One report has demonstrated that BMT can be used to treat all subtypes of pediatric leukemia and provides consensus guidelines for the transplantation of acute leukemia. We have found that allogeneic IBM-BMT plus adult Thymus Transplantation (TT) significantly increased numbers of CD8+ T cells that infiltrated the tumors and apoptotic tumor cells, and preserved strong graft-versus-tumor effects. EL-4 cells are derived from the thymoma of mice, and can induce the mimicking of leukemia in mice. We recently reported that IBM-BMT plus adult TT prevented the growth of leukemia as a result of the improved mitogen responses to both T and B cells, and significantly increased IL-2 production, and the number of donor-derived T cells.Our results indicate that allogeneic IBM-BMT plus TT can induce a strong graft-versusleukemia effect with mild graft-versus-host disease, suggesting it may be a viable strategy for the treatment of leukemia in humans.
Last date updated on July, 2014